NCT02082678View on ClinicalTrials.gov

Ondansetron for Bipolar Disorder and Alcohol Use Disorders

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Bipolar DisorderAlcohol Use DisorderDual Diagnosis
Interventions
DRUG

Ondansetron

Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.

DRUG

Placebo

Inactive ingredient matching the active medication in appearance

Trial Locations (1)

75390

The University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT02082678 - Ondansetron for Bipolar Disorder and Alcohol Use Disorders | Biotech Hunter | Biotech Hunter